Evolus touts equal efficacy for its Botox me-too drug in PhIII European/Canadian trials
Coming off the heels of a $80 million IPO to push its wrinkle-reducing drug towards the market, Evolus is trotting out data from a late …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
